Kenacort-A Injection
Triamcinolone Acetonide
10mg/ml
E.R.SQUIBB & SONS LIMITED
| Pack size | 1ml Ampoule x 5 |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 30.00 AED |
Indications
Kenacort-A Injection is used for:
Allergic and inflammatory responses, Inflammatory joint disease, Inflammatory skin conditions
Adult Dose
Intramuscular
Suppression of allergic and inflammatory disorders
Adult: As acetonide: 20-80 mg via deep IM into gluteal muscles.
Symptomatic control for hay fever
Adult: As acetonide: 40-100 mg via deep IM into gluteal muscles.
Rheumatic or arthritic disorders
Adult: 60 mg IM every 6 weeks; may be supplemented by additional 20-100 mg IM PRN
Intra-articular
Inflammatory joint diseases
Adult: As acetonide: Smaller joints: 2.5-5 mg (up to 10 mg), larger joints: 5-15 mg (up to 40 mg).
Max: 20-80 mg/treatment.
Intradermal
Inflammatory skin conditions
Adult: As acetonide: 1-3 mg/site. Max: 30 mg in total if several sites of inj used. Max: 12.5 mg/inj site. Max: 25 mg/lesion.
Child Dose
Intramuscular
Suppression of allergic and inflammatory disorders
Child: As acetonide: deep IM into gluteal muscle: initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses.
Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol.
Child: 6-12 years: 0.03-0.2 mg/kg IM every 1-7 days
>12 years: 60 mg IM every 6 weeks; may be supplemented by additional 20-100 mg IM PRN
>12 years, intralesional injection (10 mg/mL suspension): 1 mg per injection site 1 or more times weekly; not to exceed 30 mg/day
Symptomatic control for hay fever
Child: As acetonide: deep IM into gluteal muscle: initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses.
Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol.
Renal Dose
Administration
Dilute with local anesthetic (1% or 2% lidocaine without parabens) before intra-articular or intralesional injection
Dilute with D5/NS or D10/NS or NS or SWI before intralesional injection
Contra Indications
Triamcinolone Acetonide is contraindicated in patients with a sensitivity to the active or inactive ingredients. Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates (Parenteral)
Precautions
Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.
Lactation: Excreted in breast milk; use caution
Pregnancy-Lactation
Pregnancy
There are no data regarding the use of triamcinolone acetonide in pregnant women to inform a drug associated risk of adverse developmental outcomes
In animal reproductive studies from published literature, pregnant mice, rats, rabbits, or primates administered triamcinolone acetonide during organogenesis period at doses that produced exposures less than the maximum recommended human dose (MRHD) caused resorptions, decreased fetal body weight, craniofacial and/or other abnormalities such as omphalocele
Corticosteroids may result in menstrual pattern irregularities (eg, deviations in timing, duration of menses, increased/decreased blood loss)
Lactaction
There are no available data on the presence of triamcinolone acetonide in either human or animal milk, the effects on the breastfed infant, or the effects on milk production
Corticosteroids have been detected in human milk and may suppress milk production
Caution should be exercised when corticosteroids are administered to a nursing woman
Interactions
Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, beta agonists, beta-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Adverse Effects
Side effects of Triamcinolone Acetonide :
HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes.
Potentially Fatal: Acute adrenal insufficiency may be precipitated by infection or trauma in patients on long-term corticosteroid therapy or rapid withdrawal.
Mechanism of Action
Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation.
Note
Kenacort-A 10mg/ml Injection manufactured by E.R.SQUIBB & SONS LIMITED. Its generic name is Triamcinolone Acetonide. Kenacort-A is availble in United Arab Emirates.
Farmaco UAE drug index information on Kenacort-A Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.